Therapeutic Drug Monitoring

Adalimumab, infliximab

Official distribution partner of MabTrack ELISA from Sanquin Reagents
Official distribution partner of MabTrack ELISA from Sanquin Reagents

Adalimumab and infliximab are biologics with specific effectiveness against tumor necrosis factor α (TNFα), which are applied in the treatment of patients e.g. with chronic inflammatory bowel diseases, rheumatoid arthritis and psoriasis. By means of regular monitoring of the drug concentration in the blood, the optimal dose for each patient can be individually determined. Despite the good overall effectiveness of these drugs, there may be a loss of effectiveness. This is often caused by antibodies which are formed against the drugs (anti-drug antibody, ADA) and lead to a decrease of the levels of the drug’s active ingredient.

The MabTrack Level ELISA enable precise determination of concentrations of adalimumab or infliximab in patient sera. As a complementary test, the MabTrack Anti-Drug-Antibody ELISA allow specific determination of ADA against adalimumab or infliximab.

 

ProductOrder number
MabTrack Level AdalimumabED 4110-9601
MabTrack Anti-Drug-Antibody AdalimumabED 4111-4801 G
MabTrack Level InfliximabED 4120-9601
MabTrack Anti-Drug-Antibody InfliximabED 4121-4801 G